Targeting a specific metabolic pathway to treat acute myeloid leukemia.
Targeting Hexosamine Biosynthetic Pathway and O-GlcNAcylation to Treat Acute Myeloid Leukemia
This study is exploring a new way to treat acute myeloid leukemia (AML) by targeting a specific pathway that cancer cells use to survive, with the hope of making treatments more effective and safer, especially for older veterans who often struggle with current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10925521 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for acute myeloid leukemia (AML), focusing on the hexosamine biosynthetic pathway and its role in cancer cell survival. The study aims to understand how AML cells utilize this pathway for energy and growth, leading to increased resistance to current therapies. By inhibiting this pathway, the research seeks to selectively kill AML cells while sparing normal cells, potentially reducing relapse rates. The research is particularly relevant for older veterans, who have a significantly lower survival rate with existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 65 and older, particularly veterans diagnosed with acute myeloid leukemia.
Not a fit: Patients with other forms of leukemia or those who are not veterans may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, improving survival rates and quality of life for patients.
How similar studies have performed: While this approach is innovative, previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting potential for success.
Where this research is happening
Cleveland, United States
- Louis Stokes Cleveland VA Medical Center — Cleveland, United States (Active)
Researchers
- Principal investigator: Ramakrishnan, Parameswaran — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Ramakrishnan, Parameswaran
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.